The Poly (ADP-ribose) polymerase inhibitor olaparib and pan-ErbB inhibitor neratinib are highly synergistic in HER2 overexpressing epithelial ovarian carcinoma in vitro and in vivo.

导出 OA

翻译打印收藏纠错

作者： Chanhee,Han ^[1] ; Blair,McNamara ^[2] ; Stefania,Bellone ^[2] ; Justin,Harold ^[2] ; Paola,Manara ^[2] ; Tobias Max Philipp,Hartwich ^[2] ; Levent,Mutlu ^[2] ; Yang,Yang-Hartwich ^[2] ; Margherita,Zipponi ^[2] ; Cem,Demirkiran ^[2] ; Miguel Skyler Z,Verzosa ^[2] ; Gary,Altwerger ^[2] ; Elena,Ratner ^[2] ; Gloria S,Huang ^[2] ; Mitchell,Clark ^[2] ; Vaagn,Andikyan ^[2] ; Masoud,Azodi ^[2] ; Peter R,Dottino ^[2] ; Peter E,Schwartz ^[2] ; Alessandro D,Santin ^[3]

作者单位： Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale University School of Medicine, CT 06520, USA; Division of Gynecologic Oncology, Department of Gynecology and Obstetrics, Emory University School of Medicine, Atlanta, GA 30322, United States of America. ^[1] Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale University School of Medicine, CT 06520, USA. ^[2] Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale University School of Medicine, CT 06520, USA. Electronic address: alessandro.santin@yale.edu. ^[3]

关键词 HER2 Neratinib Olaparib Ovarian cancer PARP inhibitors